Novo Nordisk begins construction on $1.8bn production plant in North Carolina

WCN Editorial Team 29 Mar 2016 NORTH AMERICA BUILDINGS

Novo Nordisk, a healthcare company, has started construction on its new $1.8bn diabetes medicine production facility in Clayton, North Carolina.

The construction site is located next to the company’s existing 457,000 sq ft Clayton facility, which has been expanded several times since its inception in 1996. The new plant will measure 833,000 sq ft and have a footprint of 417,639 sq ft.

Upon fully operational in 2020, the facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk's current and future GLP-1 and insulin medicines.

It is anticipated that the project will require to 2,500 construction workers at its peak, and will create nearly 700 new permanent jobs.

Novo Nordisk president and CEO Lars Rebien Sørensen said: "As the prevalence of diabetes has grown in the US, so too has the demand for effective treatments.

"It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organization. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come."

With 11 websites and newsletters covering all the key areas within the construction industry, World Construction Industry Network is the leading global construction information resource. READ ABOUT US



World Construction Network | is a product of GlobalData. Copyright © 2022 GlobalData. All rights reserved.